Piperacillin-Tazobactam

| Spectrum of Activity* | Gram-positives including MSSA, *E. faecalis*  
|                       | Gram-negatives including *Pseudomonas*  
|                       | Anaerobes  

| Indications | Treatment of serious Gram-negative or polymicrobial infections, including mixed aerobic and anaerobic infections, where the use of other agents is not appropriate because of resistance, contraindications or adverse events  

| Not indicated | Does not cover MRSA, most *E. faecium*, VRE  
|              | *Stenotrophomonas*, Atypical pathogens such as *Legionella*  
|              | Avoid in invasive/serious ESBL infections  
|              | Avoid for serious AmpC microorganisms (*Citrobacter*, *Enterobacter* infections), even if reported as susceptible  

| Safety Considerations | Platelet dysfunction  

| Renal Dosing | Dosing adjustments required for renal impairment  

| Other Considerations | Tazobactam has poor CNS penetration: use alternative agent  